Center on Aging, MC-5215, University of Connecticut Health Center, Farmington, CT 06030, USA.
J Am Geriatr Soc. 2010 Jun;58(6):1134-43. doi: 10.1111/j.1532-5415.2010.02865.x.
To investigate the effects of testosterone supplementation on bone, body composition, muscle, physical function, and safety in older men.
Double-blind, randomized, placebo-controlled trial.
A major medical institution.
One hundred thirty-one men (mean age 77.1 +/- 7.6) with low testosterone, history of fracture, or bone mineral density (BMD) T-score less than -2.0 and frailty.
Participants received 5 mg/d of testosterone or placebo for 12 to 24 months; all received calcium (1500 mg/d diet and supplement) and cholecalciferol (1,000 IU/d).
BMD of hip, lumbar spine, and mid-radius; body composition; sex hormones, calcium-regulating hormones; bone turnover markers; strength; physical performance; and safety parameters.
Ninety-nine men (75.6%) completed 12 months, and 62 (47.3%) completed end therapy (mean 23 months; range 16-24 months for 62 who completed therapy). Study adherence was 54%, with 40% of subjects maintaining 70% or greater adherence. Testosterone and bioavailable testosterone levels at 12 months were 583 ng/dL and 157 ng/dL, respectively, in the treatment group. BMD on testosterone increased 1.4% at the femoral neck and 3.2% at the lumbar spine (P=.005) and decreased 1.3% at the mid-radius (P<.001). There was an increase in lean mass and a decrease in fat mass in the testosterone group but no differences in strength or physical performance. There were no differences in safety parameters.
Older, frail men receiving testosterone replacement increased testosterone levels and had favorable changes in body composition, modest changes in axial BMD, and no substantial changes in physical function.
研究睾酮补充对老年男性骨、身体成分、肌肉、身体功能和安全性的影响。
双盲、随机、安慰剂对照试验。
一家主要医疗机构。
131 名男性（平均年龄 77.1 +/- 7.6 岁），其睾酮水平低、有骨折史或骨密度（BMD）T 评分小于-2.0 和虚弱。
参与者接受 5 毫克/天的睾酮或安慰剂治疗 12 至 24 个月；所有人都接受钙（饮食和补充 1500 毫克/天）和胆钙化醇（1000 IU/天）。
髋部、腰椎和中桡骨的 BMD；身体成分；性激素、钙调节激素；骨转换标志物；力量；身体表现；和安全参数。
99 名男性（75.6%）完成了 12 个月的治疗，62 名（47.3%）完成了终末治疗（平均 23 个月；范围为 16-24 个月，62 名完成治疗的患者）。研究依从性为 54%，40%的受试者维持了 70%或更高的依从性。治疗组 12 个月时的睾酮和生物可利用睾酮水平分别为 583ng/dL 和 157ng/dL。睾酮治疗组的股骨颈和腰椎 BMD 分别增加 1.4%和 3.2%（P=.005），桡骨中段 BMD 减少 1.3%（P<.001）。睾酮组的瘦体重增加，脂肪量减少，但力量和身体表现没有差异。安全性参数无差异。
接受睾酮替代治疗的老年、虚弱男性增加了睾酮水平，身体成分有了有利的变化，轴向 BMD 略有变化，身体功能没有实质性变化。
